ATE413401T1 - Neue purinderivate, deren herstellungsverfahren, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue verwendung - Google Patents

Neue purinderivate, deren herstellungsverfahren, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue verwendung

Info

Publication number
ATE413401T1
ATE413401T1 AT04710901T AT04710901T ATE413401T1 AT E413401 T1 ATE413401 T1 AT E413401T1 AT 04710901 T AT04710901 T AT 04710901T AT 04710901 T AT04710901 T AT 04710901T AT E413401 T1 ATE413401 T1 AT E413401T1
Authority
AT
Austria
Prior art keywords
optionally substituted
alkyl
aryl
new
upto
Prior art date
Application number
AT04710901T
Other languages
English (en)
Inventor
Florence Bordon-Pallier
Jean-Luc Haesslein
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE413401T1 publication Critical patent/ATE413401T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04710901T 2003-02-18 2004-02-13 Neue purinderivate, deren herstellungsverfahren, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue verwendung ATE413401T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0301915A FR2851248B1 (fr) 2003-02-18 2003-02-18 Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Publications (1)

Publication Number Publication Date
ATE413401T1 true ATE413401T1 (de) 2008-11-15

Family

ID=32749627

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04710901T ATE413401T1 (de) 2003-02-18 2004-02-13 Neue purinderivate, deren herstellungsverfahren, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue verwendung

Country Status (11)

Country Link
EP (1) EP1597258B1 (de)
JP (1) JP2006517955A (de)
AT (1) ATE413401T1 (de)
AU (1) AU2004212733B2 (de)
BR (1) BRPI0407578A (de)
CA (1) CA2515610A1 (de)
DE (1) DE602004017580D1 (de)
FR (1) FR2851248B1 (de)
IL (1) IL170318A (de)
MX (1) MXPA05007519A (de)
WO (1) WO2004073595A2 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US20090111805A1 (en) * 2005-02-24 2009-04-30 Pfizer Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
GB0519245D0 (en) * 2005-09-20 2005-10-26 Vernalis R&D Ltd Purine compounds
AU2007337895C1 (en) * 2006-12-22 2014-07-31 Astex Therapeutics Limited Tricyclic amine derivatives as protein tyrosine kinase inhibitors
RU2009131738A (ru) * 2007-01-23 2011-02-27 Палау Фарма С.А. (Es) Производные пурина
US8404674B2 (en) 2007-03-07 2013-03-26 Boehringer Ingelheim International Gmbh Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof
ES2406129T3 (es) * 2007-10-05 2013-06-05 Verastem, Inc. Derivados de purina sustituidos con pirimidina
AU2009269087A1 (en) * 2008-07-07 2010-01-14 Xcovery Holding Company Llc PI3K isoform selective inhibitors
CN104507473A (zh) * 2012-02-17 2015-04-08 奇尼塔四有限责任公司 用于治疗沙粒病毒感染的抗病毒药物
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
RU2760305C1 (ru) * 2021-04-26 2021-11-23 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук (ИОС УрО РАН) 4-[(Пурин-6-ил)аминополиметиленкарбонил]-производные 3,4-дигидро-3-метил-7,8-дифтор-2H-[1,4]бензоксазина, обладающие противоопухолевой активностью

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012718A1 (en) * 1991-01-23 1992-08-06 Gensia, Inc. Adenosine kinase inhibitors
MX9709867A (es) * 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
RU2001124352A (ru) * 1999-02-01 2004-02-20 Си Ви Терапьютикс, Инк. (Us) Пуриновые ингибиторы циклин-зависимой киназы 2 и Ikb-альфа
FR2793794B1 (fr) * 1999-05-21 2001-07-27 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation
AU3938802A (en) * 2000-10-31 2002-06-03 Aventis Pharma Inc Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
FR2818642B1 (fr) * 2000-12-26 2005-07-15 Hoechst Marion Roussel Inc Nouveaux derives de la purine, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilistion

Also Published As

Publication number Publication date
AU2004212733B2 (en) 2009-12-24
AU2004212733A1 (en) 2004-09-02
MXPA05007519A (es) 2005-09-21
EP1597258B1 (de) 2008-11-05
WO2004073595A3 (fr) 2005-01-06
EP1597258A2 (de) 2005-11-23
DE602004017580D1 (de) 2008-12-18
FR2851248B1 (fr) 2005-04-08
JP2006517955A (ja) 2006-08-03
IL170318A (en) 2011-02-28
BRPI0407578A (pt) 2006-02-14
FR2851248A1 (fr) 2004-08-20
WO2004073595A2 (fr) 2004-09-02
CA2515610A1 (fr) 2004-09-02

Similar Documents

Publication Publication Date Title
ATE413401T1 (de) Neue purinderivate, deren herstellungsverfahren, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue verwendung
DE69027440D1 (de) Bizyklische pyrimidinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung
DE69627035D1 (de) Derivate von aminosäuren, sie enthaltende pharmazeutische zusammensetzungen sowie deren herstellunsgverfahren
ATE495741T1 (de) Aminoindazolderivate mit kinaseinhibierender wirkung, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
ATE447571T1 (de) Pyrroloä2,3-büpyridinderivate, die als kinaseinhibitoren wirken; verfahren zu deren herstellung und pharmazeutische zusammensetzung, die diese enthält
DE59505789D1 (de) Pyrimido [5,4-d]pyrimidine, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
ATE403648T1 (de) Substituierte dihydrochinoline als glucocorticoid-mmimetika,verfahren zu deren herstellung, pharmazeutische zubereitungen und deren verwendung
NO20063758L (no) Pyrazolo[1,5-A]pyrimidin-7-yl-amin derivater for anvendelse i behandling av proteinkinase avhengige sykdommer
DE60322359D1 (de) Imidazopyridinderivate als kinaseinhibitoren
NO308798B1 (no) Proteinkinase-C-hemmere, anvendelse av samme for fremstilling av farmasøytika samt farmasøytisk formulering omfattende samme
DE69828445D1 (de) Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
ATE353013T1 (de) Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
DK0783501T3 (da) Pyrimidonderivater med anti-fungal aktivitet
DE60103909T2 (de) 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-on- und 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5 1honderivate
DE602004012758D1 (de) Chinoxalinderivate als inhibitoren der neutrophilelastase und deren verwendung
ATE206122T1 (de) Verbindungen, die als antiproliferative mittel und als garft inhibitoren verwendbar sind
BRPI0408727A (pt) composto, processo para preparar o mesmo, composição farmacêutica, método para tratar de uma condição ou estado de doença mediados pela atividade da quinase p38 ou mediados pelas citocinas produzidas pela atividade da quinase p38, e, uso de um composto
ES2135429T3 (es) Derivados de ciclohexano sustituidos para el tratamiento de enfermedades.
DE58900636D1 (de) Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung als arzneimittel.
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
DE69217511D1 (de) Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel
ATE443041T1 (de) Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
Sakai et al. Fibroblast growth factor receptor modulators employing diamines with reduced phospholipidosis-inducing potential
ATE105838T1 (de) 6-fluor-3,5-dihydroxycarbonsäuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische präparate und zwischenprodukte.
ATE170527T1 (de) Phosphonobernsteinsäurederivate und ihre verwendung als arzneimittel

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties